Extracellular S100A1 Protein Inhibits Apoptosis in Ventricular Cardiomyocytes via Activation of the Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2)*

S100A1 is a Ca²⁺-binding protein of the EF-hand type that belongs to the S100 protein family. It is specifically expressed in the myocardium at high levels and is considered to be an important regulator of cardiac contractility. Because the S100A1 protein is released into the extracellular space during ischemic myocardial injury, we examined the cardioprotective potential of the extracellular S100A1 protein on ventricular cardiomyocytes in vitro. In this report we show that extracellularly added S100A1 protein is endocytosed into the endosomal compartment of neonatal ventricular cardiomyocytes via a Ca²⁺-dependent clathrin-mediated process. S100A1 uptake protects neonatal ventricular cardiomyocytes from 2-deoxyglucose and oxidative stress-induced apoptosis in vitro. S100A1-mediated anti-apoptotic effects involve specific activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) pro-survival pathway, including activation of phospholipase A, protein kinase C, mitogen-activated protein kinase (ERK1/2). In contrast, neither transsarcolemmal Ca²⁺ influx via the L-type channel nor protein kinase A activity seems to take part in the S100A1-mediated signaling pathway. In conclusion, this study provides evidence for the S100A1 protein serving as a novel cardioprotective factor in vitro. These findings warrant speculation that injury-dependent release of the S100A1 protein from cardiomyocytes may serve as an intrinsic mechanism to promote survival of the myocardium in vivo.

S100A1, a low molecular weight (Mᵣ 10,000) Ca²⁺-binding protein belongs to a multigenic family (21 members) of non-ubiquitous Ca²⁺-modulated proteins to form an important subclass of EF-hand proteins. Importantly, S100 proteins exhibit cell- and tissue-specific expression and have been linked to Ca²⁺-dependent regulation of a variety of S100 isoform-specific intracellular activities such as protein phosphorylation, enzyme activity, cell proliferation and differentiation, dynamics of cytoskeletal constituents, structural organization of membranes, intracellular Ca²⁺-homeostasis, and inflammation (for reviews, see Refs. 1–3). S100A1 is the most abundant S100 protein isoform in striated muscle and has been identified as a novel positive inotropic intracellular regulator of cardiac as well as skeletal muscle Ca²⁺-homeostasis and contractility (4–8).

However, growing evidence indicates that members of the S100 protein family also exert extracellular effects on their target cells (3). Although S100 proteins apparently lack the signaling sequences required for secretion, some S100 isoforms seem to follow secretory pathways that involve neither the classical endoplasmic reticulum/Golgi nor the alternative interleukin-1-like route (9). For instance, S100A8 and S100A9, expressed at high concentrations by myelomonocytic cells, are secreted by a novel tubulin-dependent pathway and then exert important roles in the regulation of inflammatory processes (9). Similarly, extracellular functions for S100B, which is secreted by astrocytes, have been described extensively (10). After secretion, S100B appears to exert both trophic and pro-survival effects on neurons via activation of the Ras/mitogen-activated protein (MAP) kinase pathway (11, 12). Neutrophilic effects have also been reported for extracellular S100A4 and S100A12 protein based on the activation of the extracellular signal-regulated protein kinase (ERK1/2) signaling pathway (13, 14).

It has been shown that the S100A1 protein is released into the extracellular space in considerable amounts during ischemic myocardial injury via an unknown mechanism (15). Based on these observations, we raised the hypothesis that the extracellular S100A1 protein may exert protective effects on myocardial cells. To address this question, the current study focuses on the characterization of the extracellular effects of S100A1 protein on cardiac myocytes and related molecular mechanisms in vitro. Indeed, our study identifies the S100A1 protein as a novel cardioprotective factor, because we could...
demonstrate for the first time that the extracellular S100A1 protein can protect cardiomyocytes from apoptosis based on Ca\(^{2+}\)-dependent clathrin-mediated endocytotic uptake resulting in a specific activation of the pro-survival ERK1/2 signaling pathway.

**EXPERIMENTAL PROCEDURES**

**Reagents**—Monodansylcadaverine (M-4008), chloropromazine (C-8138), and verapamil (V-4629) were purchased from Sigma, whereas myristoylated (Myr) protein kinase A (PKA) inhibitor (Myr-PKI; catalog number 476485), calphostin-c (catalog number 208725), U-73122 (catalog number 662035), and PD98095 (catalog number 513000) were obtained from Calbiochem. Myr-PFRCRCF was custom-made by Eurogentec (Belgium) as described previously (16, 17). Anti-receptor for advanced glycosylated end products (anti-RAGE) antibody was obtained from Chemicon (catalog number MAB5328).

**Expression and Purification of Human Recombinant S100A1 Protein**—Expression and purification of the human recombinant S100A1 protein in *Escherichia coli* were performed as described previously (6). After dialysis against PBS (pH 7.4), aliquots of purified S100A1 were stored at -80°C. Coupling of S100A1 with tetramethylrhodamine (Rh-S100A1) was carried out by Eurogentec.

**Cell Culture**—Isolation of neonatal ventricular cardiomyocytes (NVCMs) was performed as described previously (18). NVCMs were cultured for 3 days either on plastic culture dishes, glass coverslips, or Cell-Locate™ slides (Eppendorf) in Dulbecco’s modified Eagle’s medium (Biochrom) supplemented with penicillin/streptomycin (100 units/ml), 1% glucose, and 0.5% fetal calf serum (FCS Gold; PAA Laboratories GmbH) (standard medium) at 37°C in a 95% air/5% CO\(_2\) humidified atmosphere. To induce apoptosis, 2-day old cultures were either incubated in glucose-free standard medium or Dulbecco’s modified Eagle’s medium containing 2-deoxyglucose (3 mM) or H\(_2\)O\(_2\) (100 μM), respectively, for an additional 18 h. NVCMs were treated with 1 μM human recombinant S100A1 where indicated.

**Indirect Immunofluorescence and Phase Contrast Images**—3-day-old NVCMs grown on glass coverslips were incubated with Rh-S100A1 (1 μM) as indicated, washed three times with PBS (pH 7.4), fixed in 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100 in PBS. Following three PBS washes, coverslips were incubated in 0.1% bovine serum albumin for 30 min to block nonspecific sites. Subsequently, cells were labeled with either anti-α-actinin (Sigma; 1/3000), anti-transferrin (Sigma; 1/500), or anti-caveolin-3 (Santa Cruz Biotechnology; 1/500) antibodies. Following incubation of the primary antibody for 1 h in the dark, coverslips were washed four times with PBS, and then the corresponding ALEXA Fluor 488-conjugated secondary antibody (Molecular Probes; 1/800) was added for 1 h. After several washes with PBS, coverslips were mounted in Mowiol. Confocal images were obtained using a 100× oil objective on a Leica TCS SP laser-scanning confocal microscope. Digitized confocal images were processed by Leica software and Adobe Photoshop. For phase contrast images, an inverse filter was applied to enhance the contrast. Images were subsequently processed with TILLvision4.0.1 software (Till Photonics).

**Trypan Blue Exclusion, Cytochrome c Release, Caspase-3 Activity, and MTT Assay**—The fraction of dead cells was determined by counting trypan blue-stained cells on Cell-Locate™ slides. Viable NVCMs were tested for electrical excitability by field stimulation. On each Cell-Locate™ slide, a total number of at least 150 cells were inspected. Cytochrome c release and caspase-3 activity were assessed by Quantikine® M Mouse cytochrome c immunoassay (R&D Systems, catalog number MCTC0) and Caspase-3 Colorimetric Assay (R&D Systems, catalog number BSF1000), respectively, as outlined by the manufacturer’s protocol. An MTT assay based on the measurement of tetrazolium salt (MTT) was purchased from Trevigen (4890–25–K) and carried out according to the manufacturer’s protocol.

**Western Blot and Mitogen-activated Protein Kinase (MAPK) Activity**—Western blots using specific antibodies were performed to assess protein levels of phosphorylated/nonphosphorylated MAP kinases p44/42 (ERK1/2; Cell Signaling catalog number 9101/9102), p38 (Cell Signaling catalog number 9211/9212), p54/64 (SAPK/JNK; Cell Signaling catalog number 9251/9252), cardiac actin (Biogene; #A1–20.4.2) and S100A1 protein (Eurogentec; SA 5632). Cell cultures were rinsed in PBS, scraped off the dish in lysis buffer (PBS, pH 7.4, 0.5%, and 2 mM EGTA/EDTA) containing a mixture of 1% (v/v) phosphatase inhibitors (Sigma; phosphatase inhibitor mixture I/II) and protease inhibitors (1 table/5 ml) (Roche Applied Science; Mini Complete EDTA-free protease inhibitor). To determine Rh-S100A1-uptake, NVCMs were first washed extensively with EGTA/EDTA buffer (PBS, pH 7.4, and 2 mM EGTA/EDTA) and then lysed. Blots were developed with the Avidix chemiluminescence detection system (Tropix, Applied Biosystems, Foster City, CA) and quantified by densitometry.

**Statistical Analyses**—Data are presented as mean ± S.E. Unpaired Student’s t test and a two-way repeated analysis of variance (ANOVA) analysis were performed to test for differences between groups. A value of *p* < 0.05 was accepted as statistically significant.

**RESULTS**

**Ca\(^{2+}\)**-dependent Clathrin-mediated Endocytosis of Extracellular S100A1 Protein in NVCMs—Before studying the effect of extracellularly added S100A1 protein on NVCMs, the purity of human recombinant S100A1 protein was analyzed by SDS-PAGE, and the specificity of S100A1 was confirmed by Western blots probed with an custom-made antibody that specifically recognizes human S100A1 (SA5632) (data not shown) as described recently (6).

Incubation of NVCMs with 1 μM rhodamine-conjugated recombinant S100A1 protein (Rh-S100A1) for 5, 30, and 120 min in the presence of 2 mM extracellular Ca\(^{2+}\) (Ca\(^{2+}\)(3)) resulted in a vesicular accumulation of the protein in the cytosol as shown by laser-scanned confocal images (Fig. 1). Consistent with a cytotoxic distribution of internalized S100A1 protein, images taken at the level of the nucleus revealed nuclear exclusion of Rh-S100A1. Simultaneous indirect immunofluorescence labeling of Rh-S100A1-treated NVCMs with an anti-α-actinin antibody revealed the regular striated Z-line pattern typical of cardiomyocytes. Despite a reported interaction of S100A1 protein with the Z-line component capZ (19), internalized Rh-S100A1 protein seemed not to localize to the Z-lines. This suggests that internalized and endogenous S100A1 proteins are present in distinct cellular compartments, probably serving dual functions in the cardiomyocyte. To further examine the specificity of S100A1 uptake, parallel NVCM cultures were incubated with corresponding concentrations of rhodamine alone. However, in these Rh-treated cells we did not detect any dye uptake (data not shown). In contrast to NVCMs cultured in Ca\(^{2+}\)-containing standard medium, a vesicular accumulation of
Rh-S100A1 protein was not observed in cells that were kept in Ca²⁺-free medium containing 2 mM EGTA (Fig. 2, B–G). This absence indicates that the uptake of exogenous S100A1 is dependent on Ca²⁺. Analysis of homogenates from control NVCMs and cells treated with S100A1 in the presence and absence of Ca²⁺ by anti-S100A1 Western blotting further confirmed the Ca²⁺-dependence of S100A1 internalization (Fig 2A). Moreover, if NVCM cultures were incubated for 20 min with anti-S100A1 antibody (SA 5632) prior to the addition of recombinant S100A1, uptake of the S100A1 protein was also inhibited (Fig. 2H). As expected for a specific inhibition, the antibody-mediated “clearing” was dose-dependent, and, thus, an unspecific cellular uptake of the protein driven by the rhodamine tag could be excluded. In contrast, despite previous reports that have identified RAGE as a potential S100 protein receptor, intracellular uptake of S100A1 could not be prevented by a 30-min preincubation with an anti-RAGE antibody (10 μg/ml) that recognizes the ligand-binding domain of the receptor (MAB5328; data not shown) (11, 20).

To gain insight into the pathway of S100A1 internalization, Rh-S100A1-treated NVCMs were labeled with an anti-caveolin-3/Alexa Fluor 488-anti-mouse antibody (Fig. 3), which is a marker for the caveolin-mediated pathway (21). Merging the corresponding rhodamine and Alexa Fluor 488 confocal images clearly showed that the caveolin-3 staining pattern is distinct from that of Rh-S100A1 vesicles (Fig. 3C). In contrast, immunolabeling of Rh-S100A1-treated NVCMs with an anti-transferrin antibody, which is a marker for the endosomal compartment, revealed that Rh-S100A1 vesicles colocalize with transferrin and are therefore part of the endosomal compartment (Fig. 3, D–F) (22, 23). To substantiate that a clathrin-mediated uptake rather than a caveolin-dependent process is involved in S100A1 internalization, we examined the effects of two inhibitors of clathrin-mediated endocytosis, monodansylcadaverine (MDC) and chlorpromazine (CPZ) (24, 25), on the
uptake of S100A1. As illustrated by Western blots of homogenates of S100A1-treated NVCMs incubated in the presence of S100A1 (Fig. S5A), S100A1-mediated activation of ERK1/2 phosphorylation was abrogated (Fig. 6A). Furthermore, S100A1-mediated activation of ERK 1/2 could be prevented by preincubation with PD98095 (2–10 μM) (Fig. 6B), a specific inhibitor of MEK1 (26, 27).

Because the extracellular neurotrophic effects of S100A4 protein on rat hippocampal neurons depend on phospholipase C (PLC), which has also been linked to the endosomal compartment, we investigated the influence of PLC inhibition by U-73122 (5 μM) on S100A1-mediated ERK1/2 activation (13, 25). As illustrated in Fig. 6C, it appears that the inhibition of PLC completely prevented the S100A1-induced enhancement of ERK1/2 phosphorylation. Because receptor-mediated activation of PLC is known to subsequently enhance protein kinase C (PKC) activity, we next tested whether S100A1-mediated enhancement of ERK1/2 activity requires activation of PKC. Interestingly, in the presence of calphostin-c (0.5 μM), a potent inhibitor of PKC (13), S100A1-induced enhancement of ERK1/2 phosphorylation was abrogated (Fig. 6C). Because activation of cAMP-dependent protein kinase (PKA) has also been linked to ERK1/2 signaling, we likewise explored the effect of PKA inhibition on S100A1-mediated ERK1/2 activation by a cell-permeable specific PKA inhibitor (28). However, preincubation of NVCMs with the Myr-PKA inhibitor (5 μM) resulted in a dose-dependent inhibition of S100A1-mediated enhancement of ERK1/2 activity (Fig. 6C). This finding suggests that the modulation of the ERK1/2 signaling pathway by S100A1 does not involve PKA.

Transsarcolemmal Ca\(^{2+}\) influx has been shown to be another modulator of ERK1/2 signaling (28). Because the exogenous addition of the S100A1 protein to immature cardiomyocytes has been shown to increase L-type Ca\(^{2+}\)-channel (dihydropyridine receptor) activity and thus Ca\(^{2+}\) influx (29), we explored the effect of extracellularly added S100A1 protein on ERK1/2 signaling in response to inhibition of transsarcolemmal Ca\(^{2+}\)-influx. For this purpose, the dihydropyridine receptor was blocked with verapamil (5 μM), and the sodium-calcium exchanger was blocked with a cell-permeable specific sodium-calcium exchanger inhibitor, Myr-FRCRF (10 μM). In both cases, the inhibitors slightly reduced the extent of ERK1/2 phosphorylation in control cells as well as in S100A1-treated cardiomyocytes but did not perturb the S100A1-uptake and S100A1-mediated activation of ERK1/2 phosphorylation (S100A1 versus control, 3.2 ± 0.4-fold, n = 3, p < 0.01; S100A1 versus control (verapamil/Myr-FRCRF), 2.8 ± 0.2-fold, n = 3, p < 0.01) (Fig. 6D).

Taken together, our results strongly support the notion that the endocytosed S100A1 protein specifically increases ERK1/2 activity via the PLC-PKC-MEK1 pathway. In contrast, PKA and transsarcolemmal Ca\(^{2+}\)-influx did not appear to be in-
S100A1-dependent Antiapoptotic Signaling

Fig. 5. Extracellular S100A1 addition specifically increases levels of phosphorylated ERK1/2 (P-p44/42). A, the effects of extracellularly added S100A1 (1 μM) on the levels of unphosphorylated and phosphorylated p44/42 (ERK1/2; top sections), p55/46 (SAPK/JNK; middle sections), and p38 (bottom sections) are shown by Western blots of cell extracts from untreated (control) and S100A1-treated cardiomyocytes (+S100A1; 1 μM) probed with specific antibodies. Top three sections, Ca2+-mediated uptake of S100A1 leads to a 3.8 ± 0.3-fold increase in p44/42 phosphorylation (P-p44/42; center) compared with control (p < 0.01, n = 3), whereas the levels of unphosphorylated p44/42 (upper) remain constant. Inhibition of S100A1-uptake by 2 mM extracellular EGTA (lower) prevents ERK1/2 activation. Middle and bottom sections, p54/46 and p38 phosphorylation states are not affected by endocytosed S100A1. B, time-dependence of S100A1-induced activation of p44/42 phosphorylation (P-p44/42). The increase in p44/42 phosphorylation coincides with an increased level of internalized S100A1 over time. Maximal S100A1-uptake and phosphorylated p44/42 levels are reached after 10 min. C, dose-dependent activation of ERK1/2 phosphorylation. NVCs were incubated with increasing amounts of S100A1 (0.01–10 μM) for 30 min. A significant (p < 0.01) increase of phosphorylated p44/42 is detected at 1 and 10 μM S100A1 stimulation.

Involved in the S100A1-mediated activation of ERK1/2.

S100A1 Inhibits NVCM Apoptosis via ERK1/2 Signaling—Previous studies that have demonstrated that ERK1/2 activation is associated with protection from apoptosis in cardiomyocytes (26, 30–33), prompted us to examine whether S100A1-induced ERK1/2 signaling may exert cardioprotective effects on cardiomyocytes. To assess whether the addition of S100A1 provides protection from apoptotic stimuli, NVCMs were incubated in 2-deoxyglucose (2-DOG) containing glucose-free medium for 18 h as described previously (26) and in 2-DOG containing the MEK1 inhibitor PD98095. Fig. 7 shows corresponding phase contrast images of NVCMs cultured in standard medium in comparison to cells cultured in 2-DOG. The addition of S100A1 to NVCMs cultured in standard medium did not significantly alter cell morphology (Fig. 7, A and B). Apoptosis is induced when NVCMs were cultured in 2-DOG rather than standard medium (Fig. 7C), and the cells display a rounded morphology. In the presence of S100A1 (Fig. 7D), the rounding up of 2-DOG was prevented, and the cell morphology is similar to that of untreated cells cultured in standard medium (Fig. 7A). The S100A1-induced protection from apoptosis was abolished in the presence of the MEK1 inhibitor PD98095 (Fig. 7F).

The viability of NVCMs was assessed by trypan blue exclusion and electrical field stimulation (Fig. 7G). The addition of 1 μM S100A1 protein did not affect the viability of cells under standard culture conditions (S100A1-treated 117 ± 8, versus untreated 119 ± 8, each n = 5 cell locates; p values were not significant). However, compared with untreated NVCMs (100%), only ~30% of cells cultured in 2-DOG were viable and able to contract. When the cells were treated with S100A1 (1 μM), the survival rate of 2-DOG-induced apoptotic cells was ~2-fold higher. Consistent with the morphological data, S100A1-mediated rescue from apoptosis was effectively abolished by the presence of the MEK1 inhibitor PD98095 (10 μM).

As additional indicators of apoptosis, mitochondrial cytochrome c release, caspase-3, and mitochondrial dehydrogenase activity were quantified under different culture conditions (Fig. 7, H–J). If S100A1 was added to cells cultured in 2-DOG medium, the cytochrome c release and caspase-3 activity was reduced by ~2.5- and ~1.8-fold, respectively (Fig. 7, H and I). Again, the S100A1-mediated protection from apoptosis was effectively prevented by the addition of 10 μM PD98095. The presence of the inhibitor also blocked a nearly ~1.3-fold higher preservation of mitochondrial dehydrogenase activity in S100A1-treated cells compared with untreated NVCMs (Fig. 7J). In line with these results, the pretreatment of cultured cardiomyocytes with S100A1 similarly inhibited oxidative stress-induced apoptosis by H2O2 (100 μM) in our experimental setting (data not shown). In summary, these results demonstrate that the addition of the S100A1 protein to cultured neonatal ventricular cardiomyocytes protects them via the activation of ERK1/2 signaling from apoptotic stimuli.

DISCUSSION

To date, the multigene family of Ca2+-binding proteins of the EF-hand type known as S100 proteins has grown to 21 members that are differentially expressed in a large number of cell types. Individual S100 proteins are viewed as cell-specific proteins, which are implicated in the Ca2+-dependent regulation of a variety of activities in the cell (3). Recent evidence indicates that S100 proteins, once secreted or released into the extracellular space, may also exert specific effects on their target cells. For instance, extracellular S100A8 and S100A9 secreted by a novel tubulin-dependent pathway have been ascribed important functions in the regulation of inflammatory processes (9). In addition, secreted S100B, S100A4, and S100A12 have been shown to exert a neurotrophic effect on neurons (11, 13, 14). In the case of S100B, the trophic effects on neurite outgrowth were accompanied by an increased expression of the anti-apoptotic protein Bcl-2 (11). Because S100A1 is also released into the extracellular space following ischemic
myocardial injury (15), we undertook this study addressing the question of whether extracellular S100A1 may exert protective effects on cardiac cells.

Our data provide, for the first time, evidence that the extracellular addition of the S100A1 protein can protect neonatal ventricular cardiomyocytes from apoptosis in vitro via specific activation of the ERK1/2 signaling pathway. By coupling the human recombinant S100A1 protein with rhodamine, we were able to trace the uptake of S100A1 into the cytosolic compartment of cultured NVCMs. Indirect immunofluorescence staining and uptake experiments under different culture conditions revealed that the S100A1 protein is internalized via a Ca\(^{2+}\)-dependent clathrin-mediated endocytotic pathway. Interestingly, our results suggest that cell surface RAGE, which has been reported to interact with S100B (11, 20), does not seem to be involved in the endocytosis of S100A1 in NVCMs. Therefore, another cell surface receptor is likely to be responsible for S100A1 uptake in NVCMs. Recently, internalization of the S100A1 protein into embryonic murine cardiomyocytes has been shown to be associated with a decrease in membrane capacitance (29). With regard to the current study, this decrease in membrane capacitance is likely to reflect endocytotic vesicles forming at the plasma membrane, which then pinch off as clathrin-coated vesicles and eventually fuse with the endosomal compartment.

A growing body of evidence indicates that several signaling proteins involved in receptor tyrosine kinase and G-protein coupled receptor signal transduction, e.g. PLC, Ras, Raf, MEK1, and ERK1/2, are located in endosomes from where they transduce signals to the cytosol and nucleus (25). In hippocampal neurons, it has been shown that the extracellular addition of the S100A4 protein activates the ERK1/2 signaling pathway (13). Correspondingly, our data obtained from Western blots probed with antibodies that specifically recognize unphosphorylated or phosphorylated forms of ERK1/2, together with the Western blot data obtained when known upstream constituents of the MAPK signaling pathway were inhibited (Fig. 8), demonstrate that the internalized S100A1 protein specifically activates ERK1/2 in cardiomyocytes both in a time- and a dose-dependent manner. Thus, internalization of the S100A1 protein represents an important prerequisite for the activation of ERK1/2, because prevention of S100A1 endocytosis, both in Ca\(^{2+}\)-free medium and in the presence of inhibitors of clathrin-mediated endocytosis, resulted in a lack of enhanced ERK1/2 phosphorylation. In contrast, kinases involved in other signaling pathways, such as p38 and SAPK/JNK (p54/46), are not affected.

By using several specific inhibitors of intracellular signal transduction constituents (see Fig. 8), we could elucidate that S100A1-mediated activation of ERK1/2 signaling involves activation of PLC and PKC, which have been closely linked to the endosomal compartment (25). A stimulation of ERK1/2 activation by PKC has been reported previously (34). Based on our collective findings, we have developed a model of how S100A1 participates in the ERK1/2 signaling cascade (Fig. 8). As de-
picted by the model, our data also provide evidence that sarcolemmal Ca\(^{2+}\) influx mediated by the L-type channel does not participate in the S100A1-mediated enhancement of ERK1/2 phosphorylation. These findings are in contrast to work by Gomez et al., which shows that glucagon-like peptide 1 (GLP-1)-mediated activation of ERK1/2 requires Ca\(^{2+}\) influx through L-type channel in a mouse pancreatic \(\beta\)-cell line (28). Moreover, in their experimental system, inhibiting PKA activity dimin-

**Fig. 7.** Antiapoptotic effect of S100A1 protein on NVCMs. A–F, phase contrast images of NVCMs under different culture conditions. A, untreated cells in standard culture medium (containing glucose) (control). B, addition of S100A1 (1 \(\mu\)M) to NVCMs in standard medium does not significantly alter their morphol-

C, NVCMs cultured for 18 h in medium containing the apoptosis-inducing 2-DOG (3 mM) without S100A1 display a rounded morphology. D, if S100A1 is added to the cells, cells cultured in 2-DOG extend cellular processes and assume a morphology similar to that of control cells (panel A). E, untreated cells cultured as in panel C but in the presence of the MEK1 inhibitor PD98095 do not spread. F, in the presence of PD98095, 2-DOG-induced apoptosis is not overcome by the addition of S100A1. Bar, 50 \(\mu\)m. G, anti-apoptotic ef-

H, S100A1 treatment reduces apoptosis-related mitochondrial cytochrome c release by \(-2.5\)-fold (S100A1-treated 17 ± 1.1% versus untreated 61 ± 2.3%, \(n = 5\); *, \(p < 0.01\); data are expressed as the percentage of cytosolic cytochrome c from total cytochrome c was estimated at \(-230\) ng per \(10^6\) cells). This reduction is blocked by 10 \(\mu\)M PD98095 (S100A1-treated 17 ± 1.1% versus S100A1-treated/PD98095 50.4 ± 2.1%, \(n = 5\); **, \(p < 0.01\)). H, apoptosis-

I, apoptosis-related caspase-3 activity is reduced \(-1.8\)-fold by S100A1 treatment (S100A1-treated 0.37 ± 0.08 versus untreated 1.05 ± 0.1, \(n = 5\); *, \(p < 0.01\)). The anti-

J, in comparison to untreated NCVM, S100A1 treatment prevents the 2-DOG-mediated decrease in mitochondrial dehydrogenase activity (S100A1-treated 1.4 ± 0.2 versus untreated 0.6 ± 0.1, \(n = 5\); **, \(p < 0.01\)). This anti-apoptotic effect is inhibited by 10 \(\mu\)M PD98095 (S100A1-treated 1.4 ± 0.2 versus S100A1-treated/PD98095 0.4 ± 0.1, \(n = 5\); ***, \(p < 0.01\)).
The mechanism by which a considerable amount of S100A1 is released into the extracellular space during ischemic myocardial injury is yet unknown. Because other S100 proteins are secreted either by a Ca²⁺- or a tubulin-dependent pathway, one might consider a similar mechanism for myocardial S100A1 release. Based on these considerations, we hypothesize that, in vivo, S100A1 extravasation from myocardial cells under pathological conditions might promote the survival of the surrounding myocardium. Because S100A1 protein levels are reduced in heart failure (36) and S100A1 gene deletion resulted in progressive deterioration of cardiac function in vivo (8), S100A1 protein deficiency may not only result in impaired contractility of the failing heart but may also contribute to an enhanced susceptibility of injured or failing cardiomyocytes to apoptosis. Undoubtedly, elucidating the detailed molecular mechanism of myocardial S100A1 release is now imminent, as are studies that provide insight into the pathophysiological relevance of the cardioprotective effect of the S100A1 protein on cardiac cells in vivo.

REFERENCES

1. Zimmer, D. B., Cornwall, E. H., Landar, A., and Song, W. (1995) Brain Res. Bull. 37, 417–429
2. Heizmann, C. W., and Cox, J. A. (1998) Biomolecules 15, 353–397
3. Donato, R. (2003) Microcirc. Res. Tech. 60, 540–551
4. Most, P., Bernett, J., Ehlersmann, P., Pleger, S. T., Borries, M., Niosemond, F., Pieske, B., Jansen, P. M., Eshchenagen, T., Kreczewski, P., Smith, G. L., Koch, W. J., Katus, H. A., and Remppis, A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13889–13894
5. Most, P., Remppis, A., Pleger, S. T., Loefler, E., Ehlersmann, P., Bernett, J., Kleus, C., Heierhorst, J., Ruiz, P., Witt, H., Kreczewki, P., Mao, L., Rockman, H. A., Duncan, S. J., Katus, H. A., and Koch, W. J. (2003) J. Biol. Chem. 278, 33808–33812
6. Most, P., Remppis, A., Weber, C., Bernett, J., Ehlersmann, P., Pleger, S. T., Kirsch, W., Weber, M., Uttenweiler, D., Smith, G. L., Katus, H. A., and Fink, R. H. (2003) J. Biol. Chem. 278, 26356–26364
7. Remppis, A., Most, P., Loffler, E., Ehlersmann, P., Bernett, J., Pleger, S. T., Borries, M., Repp, M., Fischer, J., Koch, W. J., Smith, G. L., and Katus, H. A. (2002) Basic Res. Cardio. 97, 156–162
8. Du, X. J., Cole, T. J., Tenis, N., Gao, X. M., Kettgen, F., Kemp, B. E., and Heierhorst, J. (2002) Mol. Cell. Biol. 22, 2821–2829
9. Ramsme, A., Roth, J., Goeheler, M., Klempt, M., Hartmann, M., and Sorg, C. (1997) J. Biol. Chem. 272, 9496–9502
10. Davey, G. E., Murmann, P., and Heizmann, C. W. (2001) J. Biol. Chem. 276, 30819–30826
11. Huttunen, H. J., Kuja-Panula, J., Sorci, G., Agnetelli, A. L., Donato, R., and Rauvala, H. (2000) J. Biol. Chem. 275, 40101–40105
12. Alexanian, A. R., and Bamburg, J. R. (1999) FEBS Lett. 278, 33808–33812
13. Novitskaya, V., Grigorian, M., Kriajevska, M., Tarabykina, S., Bronstein, I., Kiewitz, R., Acklin, C., Minder, E., Huber, P. R., Schafer, B. W., and Heizmann, C. W. (2000) Biochem. Biophys. Res. Commun. 274, 865–871
14. Conner, S. D., and Schmid, S. L. (2003) Nature 422, 37–44
15. Berezin, V., Bock, E., and Lukanidin, E. (2000) J. Biol. Chem. 275, 7765–7770
16. Berezin, V., Bock, E., and Lukanidin, E. (2001) Pflugers Arch. Eur. J. Physiol. 438, 581–590
17. Berezin, V., Bock, E., and Lukanidin, E. (2001) Arch. Biochem. Biophys. 395, 127–133
18. Berezin, V., Bock, E., and Lukanidin, E. (2001) Biochem. Biophys. Res. Commun. 274, 865–871
19. Berezin, V., Bock, E., and Lukanidin, E. (2001) Pflugers Arch. Eur. J. Physiol. 438, 455–463
20. Berezin, V., Bock, E., and Lukanidin, E. (2001) J. Biol. Chem. 276, 30819–30826
21. Conner, S. D., and Schmid, S. L. (2003) Nature 422, 37–44
22. Rizzo, M. A., Shome, K., Watkins, S. C., and Romero, G. (2000) J. Biol. Chem. 275, 23918–23923
23. Bol, A., Calvo, M., and Enrich, C. (1998) FEBS Lett. 441, 34–38
24. Howe, C. L., Valletta, J. J., Rusnak, A. S., and Mobley, W. C. (2001) Neuron 32, 801–814
25. Sorkin, A., and Van Zastroev, M. (2002) Nat. Rev. Mol. Cell. Biol. 3, 600–614
26. Du, X. J., Cole, T. J., Tenis, N., Gao, X. M., Kontgen, F., Kemp, B. E., and Heierhorst, J. (2002) Mol. Cell. Biol. 22, 2821–2829
27. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Biochem. J. 351, 95–105
28. Gomez, E., Pritchard, C., and Herbert, T. P. (2002) J. Biol. Chem. 277, 48146–48151

The model suggests endocytosis of extracellular S100A1 by NVCMs via an unknown receptor. Inhibitors of the S100A1-mediated pathway are shown in red, whereas markers are given in blue.
29. Reppel, M., Remppis, A., Sasse, P., Roell, W., Most, P., Hescheler, J., Katus, H. A., and Fleischmann, B. K. (2002) *Eur. Heart J.* 23, (suppl.) 41 (Abstr. P963)

30. Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y., Kodoh, S., Tanaka, M., Shiojima, I., Hiroi, Y., and Yazaki, Y. (1997) *J. Clin. Invest.* 100, 1813–1821

31. De Windt, L. J., Lim, H. W., Haq, S., Force, T., and Molkentin, J. D. (2000) *J. Biol. Chem.* 275, 13571–13579

32. Mehrhof, F. B., Muller, P. U., Bergmann, M. W., Li, P., Wang, Y., Schmitz, W., Dietz, R., and von Harsdorf, R. (2001) *Circulation* 104, 2088–2094

33. Parrizas, M., Saltiel, A. R., and LeRoith, D. (1997) *J. Biol. Chem.* 272, 154–161

34. Braz, J. C., Bueno, O. F., De Windt, L. J., and Molkentin, J. D. (2002) *J. Cell Biol.* 156, 905–919

35. Sheng, Z., Knowlton, K., Chen, J., Hoshijima, M., Brown, J. H., and Chien, K. R. (1997) *J. Biol. Chem.* 272, 5783–5791

36. Remppis, A., Greten, T., Schafer, B. W., Hunziker, P., Erne, P., Katus, H. A., and Heizmann, C. W. (1996) *Biochim. Biophys. Acta* 1213, 253–257